Marfan syndrome (MFS; MIM# 154700) is an autosomal dominantly inherited disorder caused by mutations in the fibrillin-1 (FBN1) gene located on chromosome 15q21 that typically affects the cardiovascular, skeletal, and ocular systems (1, 2, 3). The incidence of MFS is approximately 1 per 10,000 individuals, and it does not show geographic, ethnic, or gender differences (3, 4). Although the clinical manifestations of MFS are highly diverse within affected families, the primary skeletal manifestations, such as tall stature, chest wall abnormality, and scoliosis are relatively common characteristics of MFS. And these primary skeletal manifestations affect the growth pattern in MFS.

Growth-reductive therapy with high dose sex steroids is a well-known, though still controversial, therapy. Due to the different growth pattern of MFS and the effect of growth-reductive therapy before puberty, disease-specific growth charts for MFS are needed. It would be useful for understanding the growth pattern in MFS, for predicting adult height and for planning the timing of growth-reductive therapy. Recently, only one study has presented disease-specific growth charts for MFS (5). There have been some reports that the clinical phenotype of Korean and Japanese MFS patients may differ from that of Western populations (6, 7). Therefore, we have reviewed the growth parameters of patients with MFS in Korea and generated the Korean MFS-specific growth charts.

Growth data were available from 187 males and 152 females with MFS through a retrospective review of medical records. The statistical analysis included 586 height measurements and 651 weight measurements for males and 596 height measurements and 665 weight measurements for females. The majority of anthropometric data (85.7% of the total height data, 86.1% of the total weight data) had longitudinal measurements. Approximately 4.2% of the data were available from birth to 36 months. For comparison with the general population, the 2007 Korean National Growth Chart was used (12).

The disease-specific growth chart is an important clinical tool for monitoring the growth of patients with conditions that cause growth impairment, such as Down syndrome (13, 14, 15), Turner syndrome (16), and Prader-Willi syndrome (17). In the case of MFS, Erkula et al. (5) first reported the MFS-specific growth chart in the US. These charts have generally been used in clinical centers for monitoring the growth and the effect of hormonal therapy with these syndromes.

According to Erkula et al. (5), the mean height at birth in MFS patients coincided with the 90th percentile of the general population in both genders, which indicates that excessive linear growth in MFS patients begins prenatally. However in the current study, we could not analyze the statistical differences of birth height and weight between MFS and the general population because the data of birth length and birth weight in MFS patients were not sufficient for comparison. After 2 yr of age, the 50th percentile curve for Korean MFS linear growth was above the 97 percentile of the normal group in both genders. This was analogous to the American MFS height curve (5). Furthermore, the final MFS adult heights in Korea (191.4±5.2 cm for males and 176.2±5.3 cm for females) and the American (191.3±9.0 cm for males and 175.4±8.2 cm for females) were nearly equivalent, despite the difference in mean adult heights between the countries (173.3 cm vs. 176.7 cm for males, 160.7 cm vs. 163.1 cm for females). During the two years after birth, the MFS mean height was approximately 10 cm larger than that of the general population. However, in both gender, there was no significant difference in the age to reach the 75th percentile of the final adult height between MFS and general population. In males older than 15 yr old and females older than 14 yr old, the annual difference of mean height was less than 2 cm, so the timing of the cessation of meaningful linear growth was similar to both in general population and MFS. Therefore, our study supports the American data, in which the above average height in MFS patients was obtained through early rapid growth and a broader and higher growth velocity of preadolescent and adolescent periods (5). Regarding body mass, although the mean body weight of MFS patients was larger than that of the general population in males and females, the gap of the mean weight curve was small against the height curve, especially for females. These results may partially explain marfanoid features such as tallness and a slender figure. In reports about ethnic phenotype differences in Korean and Japanese MFS as compared to the Western MFS population, Korean and Japanese MFS patients had a lower frequency of skeletal manifestations such as arm span to height ratio, scoliosis, reduced extension at the elbows, and joint hypermobility (6, 7). However, in this study, the growth curve, pattern, and even final adult height were nearly analogous to those of America.

To our knowledge, this study constitutes the first growth chart data for Korean patients with MFS, and there was no disease-specific growth chart for Asian MFS patients before this study. However, the study has several limitations. First, the study was not performed among the nationwide institutions in Korea. Most of the MFS patients have been referred to Marfan clinic in our hospital when they are diagnosed MFS, because our institution has the biggest MFS clinic in Korea and the patients come from all around Korea. Therefore, it is regarded that our charts may represent the data of Korean MFS patients. Second, we did not have sufficient longitudinal data during infancy included in the birth data; because except for some patients who received an early genetic diagnosis due to family history of MFS or those with a severe phenotype, the diagnosis of infant MFS is very difficult. Therefore, our longitudinal growth data of the period during first 24 months, when height and body mass growth were the most active, was relatively insufficient compared with that of the subsequent period. Third, we had difficulty interpreting the growth pattern due to the lack of reference data about growth velocity in Korean children, so we could not account for the difference of the prepubertal and pubertal growth peak between MFS patients and the general population. Finally, we could not obtain radiologic findings for the identification of skeletal maturity, such as bone age, because the study was of a retrospective design. Therefore, further study is needed on multicenter based, with a prospective design, including sufficient anthropometric data on the birth and infant period and the bone age data.

Despite these limitations, we developed the first disease-specific growth charts for Korean MFS. We believe that the charts can be applied to those with MFS and to those treated with sex steroid hormone for growth reductive therapy.